Navigation Links
Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
Date:5/15/2009

Results from Phase 2 Clinical Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Featured in Oral Presentations

SOUTH SAN FRANCISCO, May 15 /PRNewswire/ -- Proteolix, Inc. today announced that data from clinical trials of carfilzomib in multiple myeloma and advanced solid tumors will be presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 29 - June 2, 2009 in Orlando, Florida. Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors and is currently enrolling patients in an accelerated approval study in relapsed/refractory multiple myeloma and Phase 2 clinical studies in relapsed multiple myeloma and other malignancies.

Of note, results from Proteolix's Phase 2 study of carfilzomib for the treatment of patients with relapsed and refractory multiple myeloma will be presented on Monday, June 1 during an oral session by Sundar Jagannath, M.D., Chief of the Multiple Myeloma Program, Bone Marrow and Blood Stem Cell Transplantation at St. Vincent's Comprehensive Cancer Center in New York. The Phase 2 trial is an open-label multi-center study of single-agent carfilzomib in patients who have previously failed at least two prior treatments, containing bortezomib and either lenalidomide or thalidomide, and are refractory to their last treatment. In addition, results from a Phase Ib/II study of carfilzomib in patients with selected advanced metastatic solid tumors will be presented on Saturday, May 30 during an oral session by Peter Rosen, M.D., Medical Director, Tower Cancer Research Foundation and Emeritus Professor, UCLA.

A complete list of the company's oral and poster presentations at ASCO follows:

    Oral Presentations
      Saturday, May 30, 2009 at 5:00 p.m. ET
      Track: Developmental Therapeutics
      Session: Developmental Therapeutics: Molecular
'/>"/>
SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
2. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
4. Proteolix Raises $79 Million in Series C Financing
5. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. China Biologic Products to Present at CCG IRs China Rising Conference and Oppenheimers China Dragon Call Conference in New York
8. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
9. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
10. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
11. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 The ... today with $25,000 to fund a translational research ... in 2011, the gift was presented at the ... Annual Meeting in Colorado Springs, CO. ... in neurointerventional approaches to neurovascular conditions, SNIS formed ...
(Date:7/31/2014)... , July 31, 2014 Rogne Bioscience, ... Francisco Bay Area , has acquired a licence ... Oxford,s commercialisation company. The potent anti-inflammatory activity of the ... at the University of Oxford,s Sir William Dunn ... which has raised over $1.5 million in seed financing, ...
(Date:7/31/2014)... 31, 2014 North Shore Towers, a luxury ... with GI Energy, one of the nation’s leading combined heating ... upgrade of its 43-year-old CHP system. The original CHP system ... effort to extend the life of the plant, GI Energy ... electrical and heat recovery equipment, while maintaining continuous operation of ...
(Date:7/31/2014)... 31, 2014 Research and Markets ... Market 2014-2018" report to their offering. ... the study of the genetic material or genomes of ... basis for the discovery and development of diagnostic and ... health conditions. Genomics is supported by three major product ...
Breaking Biology Technology:SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... ... Just Test Instruments , ... (Vocus) April 25, 2010 -- Responding to the recent rash of reports of quality failures ... consultations on how to develop and maintain strict gage R&R for entire assembly and test ...
... PLANO, Texas , April 27 A non-profit organization is ... the full amount of its corporate donations.  "Unlike Coca-Cola, Pepsi refuses to ... Greg Quinlan , President of Parents and Friends of Ex-Gays & ... , "This ...
... April 27 Two months after launching a strategic review of ... has signed an agreement to sell United Media Licensing for $175 million ... , , ... the family of the late Charles Schulz , who created the beloved ...
Cached Biology Technology:InterTech Service to Counter Widely Reported Problems in Automotive, Medical Device and Other Industries Requiring Rigorous Quality Standards 2Pepsi Urged to Follow Example of Coca-Cola and Stop Hiding Corporate Donations 2Scripps Announces Sale of United Media's Licensing Business for $175 Million 2Scripps Announces Sale of United Media's Licensing Business for $175 Million 3
(Date:8/1/2014)... UC Davis Center for Neuroscience and Department of ... Engineering Faculty Fellowship from the U.S. Department of ... new work on learning and memory in Ranganath,s ... new project aims to connect neural oscillations, which ... cortex and hippocampus, brain regions that are known ...
(Date:8/1/2014)... Scientists examining a taxonomically confused group of marine ... science: the Australian humpback dolphin, Sousa sahulensis ... Clymene Enterprises. , The study describing the ... 17-year long systematic examination of all available historical ... dolphinsa widespread group of coastal cetaceans ranging from ...
(Date:8/1/2014)... research will provide enormous opportunities for both biological ... replicate any other cells in the body, offering ... spinal cords, treating kidney, liver and lung diseases ... profit is staggering. Prof. Jinhui Chen from Indiana ... research still faces myriad biological, ethical, legal, political, ...
Breaking Biology News(10 mins):Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3
... 15, 2013 A team of investigators systematically analyzed the ... in a rigorous and controlled study of postmenopausal women. They ... symptoms reported by the participants. Their results are published in ... . The influence of low calcium and vitamin D ...
... more soft drinks per capita than people in any ... of all ages, including very young children. Although ... suicidal thoughts in adolescents, the relationship had not been ... for publication in The Journal of Pediatric s ...
... 15, 2013) Primary results from a new ... diabetes treated with the monoclonal antibody teplizumab (MacroGenics, ... of islet cell function, compared to controls. Further ... group that demonstrated especially robust responses ("responders"), suggesting ...
Cached Biology News:Calcium plus vitamin D supplementation does not reduce joint symptoms in postmenopausal women 2Soft drinks and behavioral problems in young children 2ITN type 1 diabetes study identifies subset of patients with strong response to therapy 2ITN type 1 diabetes study identifies subset of patients with strong response to therapy 3
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
...
Request Info...
Human RUNX2/CBFA1 MAb (Clone 232902)...
Biology Products: